Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Bladder Cancer, October 2026

Free Subscription


Abstracts

Retrieve all available abstracts of the following 264 articles:
HTML format


 

Single Articles

  1. WU S, Fu S, Shi H, Gong Y, et al
    Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies.
    Front Immunol. 2026;17:1920567.
    PubMed    
    Abstract available

  2. ERMIS O, Aybal HC, Yuan CY, Tozsin A, et al
    Simultaneous surgery for NMIBC and BOO: evaluating surgical safety to oncological benefit.
    Minerva Urol Nephrol. 2026;78:484-497.
    PubMed    
    Abstract available

  3. SCILIPOTI P, Slusarczyk A, Subiela JD, Longoni M, et al
    Surrogacy of intermediate clinical endpoints for overall survival in BCG-naive high-risk non-muscle-invasive bladder cancer.
    World J Urol. 2026;44:721.
    PubMed    
    Abstract available

  4. ELMASMOUDI J, Merseburger AS
    Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.
    World J Urol. 2026;44:722.
    PubMed    
    Abstract available

  5. SCHOLTES MP, Koedoot E, Ceton LJ, Sijsenaar TJP, et al
    Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.
    Eur Urol Open Sci. 2026;93:3-11.
    PubMed    
    Abstract available

  6. HAU AM, Nakasaki M, Nakashima K, Krish G, et al
    Corrigendum to "Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition" Volume 35, Issue 10, October 2017, Pages 593-599.
    Urol Oncol. 2026 Oct 1:S1078-1439(26)00729-5. doi: 10.1016/j.urolonc.2026.
    PubMed    


  7. CLARK PE
    Management of Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:xv.
    PubMed    


  8. LOUGHLIN KR
    Muscle-Invasive Bladder Cancer: The Marriage of Surgery and Science.
    Urol Clin North Am. 2026;53:xiii-xiv.
    PubMed    


  9. SUPERDOCK M, Iyer G, Milowsky MI
    New and Novel Agents for Advanced Bladder Cancer.
    Urol Clin North Am. 2026;53:635-648.
    PubMed    
    Abstract available

  10. ROESSLER N, von Deimling M, Miszczyk M, Vetterlein MW, et al
    The Role of Surgery in Locally Advanced and Oligometastatic Bladder Cancer.
    Urol Clin North Am. 2026;53:625-634.
    PubMed    
    Abstract available

  11. DUBIC MG, Ward MC, Riggs S
    Trimodal Therapy for Muscle Invasive Bladder Cancer: An Update on Current Practices and Future Directions.
    Urol Clin North Am. 2026;53:613-624.
    PubMed    
    Abstract available

  12. ZHU A, Eraky A, Gabriel PE, Sfakianos JP, et al
    The Role of Biomarkers in the Management of Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:601-612.
    PubMed    
    Abstract available

  13. ATIQ SO, Miller EJ, Anker JF, Galsky MD, et al
    Adjuvant Therapy in Patients after Cystectomy.
    Urol Clin North Am. 2026;53:593-600.
    PubMed    
    Abstract available

  14. MCSWEENEY ST, Aydogdu C, Bole R, Bukavina L, et al
    Sexual Function Preservation After Cystectomy.
    Urol Clin North Am. 2026;53:571-582.
    PubMed    
    Abstract available

  15. GHASEMZADEH A, Bochner BH
    What Is the Proper Extent of Lymph Node Dissection During a Radical Cystectomy for Bladder Cancer?
    Urol Clin North Am. 2026;53:561-569.
    PubMed    
    Abstract available

  16. SADIQ S, Nativ O, Ritch CR
    Open and Robotic Radical Cystectomy for Muscle-Invasive Bladder Cancer: Techniques, Outcomes, and Evidence.
    Urol Clin North Am. 2026;53:551-559.
    PubMed    
    Abstract available

  17. CHUNG R, Zibelman MR, Wong JK, Kutikov A, et al
    Advancements in Bladder-Sparing Strategies for Muscle-Invasive Bladder Cancer: A Comprehensive Review.
    Urol Clin North Am. 2026;53:539-549.
    PubMed    
    Abstract available

  18. BRITTON CJ, Galloway LAS, Luckenbaugh AN
    Prehabilitation and Patient Optimization for Cystectomy.
    Urol Clin North Am. 2026;53:527-538.
    PubMed    
    Abstract available

  19. EBER J, Matulay JT
    Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: Current Evidence, Evolving Strategies, and Future Directions.
    Urol Clin North Am. 2026;53:517-526.
    PubMed    
    Abstract available

  20. ERNANDEZ J, Xiang L, Adler R, Hsu J, et al
    Significance of dementia and frailty on postoperative care trajectories and burden among older adults undergoing radical cystectomy for bladder cancer.
    J Geriatr Oncol. 2026;18:104389.
    PubMed    
    Abstract available

  21. LI R, Linscott J, Murthy P, Rose K, et al
    Evaluation of Urinary Circulating Tumor DNA to Detect Minimal Residual Disease in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.
    medRxiv [Preprint]. 2026 Sep 11:2026.09.09.26362655.
    PubMed    
    Abstract available

  22. DEITER CS, de Jong FC, Olislagers M, Jordan KR, et al
    Stromal innervation is prognostic in non-muscle-invasive bladder cancer and predicted by a distinct microenvironmental transcriptomic signature.
    bioRxiv [Preprint]. 2026 Sep 22:2026.09.21.751588.
    PubMed    
    Abstract available

  23. SOMEYA R, Tanaka E, Yamazak M, Yokoi T, et al
    [URINARY RETENTION FOLLOWING TRANSURETHRAL RESECTION OF THE BLADDER TUMOR].
    Hinyokika Kiyo. 2026;72:269-271.
    PubMed    
    Abstract available

  24. SHAIKH AN, Ginayatova I, Malikova I, Kriajevska M, et al
    Novel Approaches in Bladder Cancer Diagnosis and Treatment.
    Curr Med Chem. 2026 Sep 29. doi: 10.2174/0109298673474262260909061628.
    PubMed    
    Abstract available

  25. ASLAM N, Kafagi AH, Khela A, Montague R, et al
    Metastatic muscle invasive bladder cancer in pregnancy.
    BMJ Case Rep. 2026;19:e275274.
    PubMed    
    Abstract available

  26. FRISCH D, Fronstin M, Zema C
    Agentic AI for Clinical Outcomes Research, Population Health Management Analyses With Large Administrative Databases, and Generating Epidemiological Estimates of Diseases: Feasibility and Validation Study.
    J Med Internet Res. 2026;28:e100284.
    PubMed    
    Abstract available

  27. MORGAN TM, Wang CY, Yapici HO, Lilley J, et al
    Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy.
    Urol Oncol. 2026;44:960-967.
    PubMed    
    Abstract available

  28. WU Y, Han W, Xiong S, He Y, et al
    Urine Methylation Test for Urothelial Cancer Diagnosis and Surveillance.
    JAMA Netw Open. 2026;9:e2636786.
    PubMed    
    Abstract available

  29. ZHANG M, Chen Z, Chen Y, Zhou Y, et al
    Longitudinal data on health-related quality of life and its association with time to readmission in bladder perfusion patients.
    Support Care Cancer. 2026;34:1032.
    PubMed    
    Abstract available

  30. JAMBALE U, Thimmappa SC
    Phytochemical Profiling, Antioxidant Activity and Cytotoxic Potential of Chloroxylon swietenia DC. Stem Extracts Against Bladder Cancer Cell Lines.
    Biomed Chromatogr. 2026;40:e70616.
    PubMed    
    Abstract available

  31. MOHAMMED MS, Abouhashim NS, Elfeky MA
    Evaluation of GATA3 and HER-2 Immunohistochemical Expression as Prognostic Markers in Urothelial Carcinoma of the Urinary Bladder.
    Asian Pac J Cancer Prev. 2026;27:3273-3279.
    PubMed    
    Abstract available

  32. LUO H, Liu X, Du Y
    Cascade Catalytic Nanozyme Amplifies Ferroptosis Immunotherapy in Bladder Cancer.
    J Biomed Mater Res A. 2026;114:e70164.
    PubMed    
    Abstract available

  33. LINGEFELT S, Nystrand V, Alamdari F, Svensson J, et al
    No urethral recurrences in complete responders after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer.
    Scand J Urol. 2026;61:230-238.
    PubMed    
    Abstract available

  34. ZHU Y, Shang J, Zhang X, Tu S, et al
    Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer.
    J Cancer. 2026;17:1720-1732.
    PubMed    
    Abstract available

  35. GOUNNI MY, Bourimi C, Tariqi R, Bakouch M, et al
    A false alarm in bladder cancer surveillance: eosinophilic cystitis after intravesical BCG instillations.
    J Surg Case Rep. 2026;2026:rjag855.
    PubMed    


  36. LI S, Peng H, Li G, Wan Z, et al
    A candidate PPARgamma to GPX4 axis in ferroptosis suppression and platinum resistance in bladder cancer: evidence appraisal and a testable research agenda.
    J Cancer. 2026;17:1797-1807.
    PubMed    
    Abstract available

  37. LI J, Tang C, Yang L, Song C, et al
    ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025.
    Front Oncol. 2026;16:1906152.
    PubMed    
    Abstract available

  38. MAO D, Chen R, Guan F, Sun J, et al
    Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1876253.
    PubMed    
    Abstract available

  39. ACQUISTAPACE E, Bernardini B, Piccioni F, Pastore M, et al
    Exploring the Role of the Nurse Case Manager in the Care Experience of Patients Undergoing Radical Cystectomy: A Qualitative Study.
    Nurs Open. 2026;13:e70821.
    PubMed    
    Abstract available

  40. BIEST AMD, Xylinas E, Gabriel PE
    SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL AFTER BCG FAILURE NON-MUSCLE INVASIVE BLADDER CANCER: ONCOLOGICAL OUTCOMES AND SAFETY PROFILE.
    Fr J Urol. 2026 Sep 28:103229. doi: 10.1016/j.fjurol.2026.103229.
    PubMed    
    Abstract available

  41. STOJKOVA O, Borcsok J, Sztupinszki Z, Diossy M, et al
    Identification of an ERCC2 Mutation-Associated Mutational Signature of Nucleotide Excision Repair Deficiency in Targeted Panel Sequencing Data.
    JCO Precis Oncol. 2026;10:e2600329.
    PubMed    
    Abstract available

  42. HEER R, Farrokhi M
    Global trends and hotspots in bladder cancer: A bibliometric analysis (2016-2025).
    Urologia. 2026 Sep 28:3915603261483766. doi: 10.1177/03915603261483766.
    PubMed    
    Abstract available

  43. DING W, Zhang X, Wu H, Zhou C, et al
    Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment.
    Int J Nanomedicine. 2026;21:616713.
    PubMed    
    Abstract available


  44. Correction to "Gut Parabacteroides distasonis-Derived Indole-3-Acetic Acid Promotes Phospholipid Remodeling and Enhances Ferroptosis Sensitivity via the AhR?FASN Axis in Bladder Cancer".
    Adv Sci (Weinh). 2026 Sep 27:e77485. doi: 10.1002/advs.77485.
    PubMed    


  45. WANG L, Liu X, Zhu T, Su Z, et al
    Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer.
    Adv Sci (Weinh). 2026 Sep 27:e77833. doi: 10.1002/advs.77833.
    PubMed    
    Abstract available

  46. NAKANISHI Y, Kawashima Y, Shinohara M, Hagiwara K, et al
    Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report.
    IJU Case Rep. 2026;9:e70270.
    PubMed    
    Abstract available

  47. GONTERO P, Babjuk M
    Reply to Roberto M. Scarpa's Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Exp
    Eur Urol Oncol. 2026 Sep 26:S2588-9311(26)00243.
    PubMed    


  48. MANTZ L, Zhu A, Mercaldo ND, Marquardt PA, et al
    Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer.
    Urol Oncol. 2026;44:946-959.
    PubMed    
    Abstract available

  49. ERYILMAZ R, Keles MF, Aslan R, Huyut Z, et al
    Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.
    Urol Oncol. 2026;44:939-945.
    PubMed    
    Abstract available

  50. KAUR N, Aravind A, Jain SP
    Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature.
    J Hematop. 2026;19:59.
    PubMed    
    Abstract available

  51. JI Y, Zhang Y, Liu X, Lv Z, et al
    Single-cell and bulk transcriptomic analyses define an IFI27-centered interferon-response epithelial state in bladder cancer and its transcriptional response to irradiation.
    Front Cell Dev Biol. 2026;14:1920354.
    PubMed    
    Abstract available

  52. WU X, Sun T, Liu Z
    Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer.
    Front Immunol. 2026;17:1891824.
    PubMed    
    Abstract available

  53. TICHIL BP, Besleaga A, Gheorghiu I, Chiorean AD, et al
    Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study.
    J Clin Med. 2026;15:7117.
    PubMed    
    Abstract available

  54. PALACKA P, Kovacova Ilijew H, Mikolaskova I, Suchankova M, et al
    The Role of Circulating Extracellular DNA in Patients with Bladder Cancer: Clinical Associations and Exploratory Links with Heart Rate Variability.
    Cancers (Basel). 2026;18:2952.
    PubMed    
    Abstract available

  55. TATAR AC, Voidazan S, Raicea A, Popelea MC, et al
    Immunohistochemistry-Based Molecular Classification of Muscle-Invasive Bladder Urothelial Carcinoma: Survival Trends Across Molecular Subtypes.
    Int J Mol Sci. 2026;27:8082.
    PubMed    
    Abstract available

  56. BILYALOV A, Kotov A, Bodunova N, Zingerenko M, et al
    Molecular Classifications and Candidate Biomarkers for Personalizing BCG Therapy in Non-Muscle-Invasive Bladder Cancer.
    Biomedicines. 2026;14:2098.
    PubMed    
    Abstract available

  57. SZACHNIEWICZ M, Baran M, Gagat M, Halas-Wisniewska M, et al
    Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells.
    Biomedicines. 2026;14:2037.
    PubMed    
    Abstract available

  58. SAITO R, Sano T, Kanno T, Aizawa R, et al
    Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma.
    Int J Clin Oncol. 2026;31:2114-2125.
    PubMed    
    Abstract available

  59. ERAKY A, Mehrazin R, Tillu N, Wagaskar VG, et al
    The Hood Technique for Robot-Assisted Radical Cystoprostatectomy with Intracorporeal Neobladder.
    J Endourol. 2026;40:1156-1163.
    PubMed    
    Abstract available

  60. ZHANG K, Li H, Ma Z, Yu Y, et al
    Metabolic Reprogramming by Engineered Probiotics Potentiates Tumor Chemodynamic Immunotherapy.
    Adv Mater. 2026;38:e74353.
    PubMed    
    Abstract available

  61. ASLAN S, Eryuruk U, Park SY, Arita Y, et al
    VI-RADS and beyond in bladder MRI: a pictorial review of quality control, response assessment, and artificial intelligence.
    Eur J Radiol. 2026;204:113114.
    PubMed    
    Abstract available

  62. HUANG W, Fu W, Zhang X, Sun H, et al
    Validation and predictive modeling of a portable bladder scanner for precision bladder management in pelvic radiotherapy.
    Br J Radiol. 2026;99:2155-2163.
    PubMed    
    Abstract available

  63. CONTIERI R, Gontero P, Hurle R, Afferi L, et al
    Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.
    Nat Rev Urol. 2026;23:691-696.
    PubMed    
    Abstract available

  64. ROESSLER N, Miszczyk M, Miyajima K, Alfarhan AR, et al
    The Influence of Urinary Diversion Type on Body Image and Decision Regret Following Radical Cystectomy: A Systematic Review.
    Eur Urol Focus. 2026;12:785-795.
    PubMed    
    Abstract available

  65. MAIORANO BA, Necchi A
    Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer.
    ESMO Open. 2026;11:108597.
    PubMed    
    Abstract available

  66. ROSHANSHAD A
    Advanced Diffusion MRI-based MR Cytometry for Quantitative Microstructural Assessment and Grading of Bladder Cancer.
    Radiol Imaging Cancer. 2026;8:e269023.
    PubMed    


  67. SHI L, Chen C, Li L, Chen J, et al
    Effects of Acupoint Application on Lower Urinary Tract Symptoms in Patients Undergoing Intravesical Instillation After Bladder Cancer Surgery: A Randomized Crossover Exploratory Study.
    Pain Res Manag. 2026;2026:e5079749.
    PubMed    
    Abstract available


  68. Correction to "MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model".
    IUBMB Life. 2026;78:e70134.
    PubMed    


  69. KIM MS, Lim DG, Jung SI, Hwang EC, et al
    Screening Bacteriuria Using the Sysmex UF-5000 during Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer.
    Chonnam Med J. 2026;62:99-106.
    PubMed    
    Abstract available

  70. BAI M, Liu T, Wu H, Yang X, et al
    IGF2BP2 remodels the lung metastatic immune microenvironment to promote bladder cancer metastasis.
    Cell Mol Immunol. 2026 Oct 9. doi: 10.1038/s41423-026-01474.
    PubMed    
    Abstract available

  71. YEOM JY, Kim YU, Kim J, Min J, et al
    Effect of nefopam on postoperative catheter-related bladder discomfort after transurethral resection of the bladder under general anesthesia: A randomized controlled trial.
    J Int Med Res. 2026;54:3000605261495728.
    PubMed    
    Abstract available

  72. VAEZI A, Mossavarali S, Raznahan M, Haddad M, et al
    Log Odds of Positive Lymph Nodes as a Novel Prognostic Predictor for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2026 Sep 21:102664. doi: 10.1016/j.clgc.2026.102664.
    PubMed    
    Abstract available

  73. GUZMAN T, McSweeney S, Aydogdu C, Diaz G, et al
    Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns.
    Urol Oncol. 2026 Oct 8:S1078-1439(26)00713-1. doi: 10.1016/j.urolonc.2026.
    PubMed    
    Abstract available

  74. ZUGMAN M, Kirche Duarte I, Baccaglini W
    The cost of intensification in high-risk non-muscle-invasive bladder cancer.
    ESMO Open. 2026;11:108598.
    PubMed    


  75. QIE Y, Jia K, Huang S, Zhao J, et al
    Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2026 Oct 8. doi: 10.1001/jamaoncol.2026.3909.
    PubMed    
    Abstract available

  76. GENG H, Wu Y, Ma J, Zhang W, et al
    Exosomal circ55033 promotes cigarette smoke-induced bladder cancer by modulating EMT and stem cell properties.
    Med Oncol. 2026;43:326.
    PubMed    
    Abstract available

  77. GORE JL, Thompson A, Kelkar SS, Chirikov V, et al
    Characteristics and Treatment Patterns of Patients with Muscle-Invasive Bladder Cancer in the United States: A Real-World Cohort Study.
    Pragmat Obs Res. 2026;17:617060.
    PubMed    
    Abstract available

  78. JEONG JI, Lee J, Oh MH, Cho HD, et al
    MITF-Overexpressing Perivascular Epithelioid Cell Tumor of the Urinary Bladder Lacking TSC1/TSC2 Alterations and TFE3 Rearrangement: A Case Report and Review of the Literature.
    Pathol Int. 2026;76:e70187.
    PubMed    
    Abstract available

  79. FU S, Tan Z, Shi H, Chen J, et al
    Retraction Note: Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.
    NPJ Precis Oncol. 2026;10:377.
    PubMed    


  80. ZHANG XZ, Xiang JA, Yang LC, Li YD, et al
    Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence.
    Front Pharmacol. 2026;17:1921622.
    PubMed    
    Abstract available

  81. WANG H, Liu H, Ma X, Wang W, et al
    Structure-based virtual screening identifies ethyl rosmarinate as a SLC1A6-targeted therapeutic candidate for bladder cancer.
    Front Pharmacol. 2026;17:1895264.
    PubMed    
    Abstract available

  82. LI S, Zhang Y, Mao T, Wei J, et al
    Aromatic amine exposure and bladder cancer: a review of recent advances in epidemiology, pathogenesis, and prevention.
    Front Cell Dev Biol. 2026;14:1914792.
    PubMed    
    Abstract available

  83. RAGGI D, Crupi E, Dyrskjot L
    ctDNA in muscle-invasive bladder cancer - clinically actionable, not yet standardized.
    Nat Rev Urol. 2026 Oct 6. doi: 10.1038/s41585-026-01197.
    PubMed    


  84. CRONIN C, Lokeshwar SD, Calagua C, Garman TS, et al
    Adamantinoma-like Ewing sarcoma of the bladder.
    BMJ Case Rep. 2026;19:e270671.
    PubMed    
    Abstract available

  85. MOCHIZUKI T, Ishiguro Y, Takeshima T, Hashizume A, et al
    Elevated expression of olfactory receptor 51T1 is associated with malignant potential of bladder cancer.
    Cancer Treat Res Commun. 2026;49:101467.
    PubMed    
    Abstract available

  86. ZENGERLING F
    [Blue versus white light during transurethral resection of nonmuscle invasive bladder cancer].
    Urologie. 2026 Oct 6. doi: 10.1007/s00120-026-02938.
    PubMed    


  87. PENG Z, Jia R, Zhang T, Yang J, et al
    CNOT4 Suppresses Bladder Cancer Progression by Promoting Ubiquitination-Mediated Degradation of EIF2AK2 and Inhibiting Autophagy.
    Mol Carcinog. 2026 Oct 6. doi: 10.1002/mc.70187.
    PubMed    
    Abstract available

  88. ZHU K, Zhang Y, Wang Y, Chen L, et al
    Shared decision-making experiences regarding urinary diversion among Chinese patients with muscle-invasive bladder cancer: A qualitative study.
    Asia Pac J Oncol Nurs. 2026;13:101024.
    PubMed    
    Abstract available

  89. ENGELS EA, Burkett S, Ramanujan VK, Yu KJ, et al
    Donor-derived bladder cancer following kidney transplantation.
    Urol Case Rep. 2026;69:103618.
    PubMed    
    Abstract available

  90. DU T, She Y, Li H, Liu X, et al
    Active bacteria-delivered nanosystems for multimodal bladder cancer therapy.
    Sci Bull (Beijing). 2026 Sep 22:S2095-9273(26)01178.
    PubMed    


  91. MATHISEN IF, Koll FJ, Mayer RS, Schulz MH, et al
    Dual-Foundation-Model Ensemble Predicts Gene Expression in Muscle-Invasive Bladder Cancer for Patient Outcome Stratification.
    Mod Pathol. 2026 Oct 5:101092. doi: 10.1016/j.modpat.2026.101092.
    PubMed    
    Abstract available

  92. PYRGIDIS N, Engelmann P, Puhr-Westerheide D, Ebner B, et al
    The effect of ureteral stenting on the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors involving the ureteral orifice.
    World J Urol. 2026;44:725.
    PubMed    
    Abstract available

  93. WEI B, Liu T, Chang X, Guo L, et al
    Celastrol Sensitizes Bladder Cancer to Gemcitabine by Regulating LINC00839-Mediated Homologous Recombination DNA Repair.
    Biochemistry (Mosc). 2026;91:1704-1715.
    PubMed    
    Abstract available

  94. YANG Y, Han L, Li J, Xue J, et al
    Social alienation among people with bladder cancer: A combined structural equation modeling and fuzzy-set qualitative comparative analysis.
    Asia Pac J Oncol Nurs. 2026;13:101025.
    PubMed    
    Abstract available

  95. XU X, Hao HY, Chen HY
    The clinical landscape of bladder cancer treatment: a brief report on new developments and future perspectives in pharmaceutical interventions.
    Front Oncol. 2026;16:1747070.
    PubMed    
    Abstract available

  96. SHI G, Wu Y, Wang Y, Wang S, et al
    The deubiquitinating enzyme UCHL3 promotes bladder cancer progression and glycolysis through enhancing PKM2 protein stability.
    Front Oncol. 2026;16:1883763.
    PubMed    
    Abstract available

  97. LIU KJ, Shi WY, Nesselbush MC, Phillips NA, et al
    Urine cell-free RNA for bladder cancer detection and treatment response prediction.
    Nat Med. 2026 Oct 2. doi: 10.1038/s41591-026-04673.
    PubMed    
    Abstract available

  98. ZARKA J, Childs DS, Muniz Rincon M, Tarhini A, et al
    Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework.
    Oncologist. 2026;31:oyag371.
    PubMed    
    Abstract available

  99. LI W, Chen Z, Deng M, Wang S, et al
    Sodium arsenite inhibits ALKBH7 increasing tRNA m(2)(2)G methylation in mitochondrial respiratory chain complex-flankng to drive malignant phenotype of bladder epithelial cells.
    Chem Biol Interact. 2026;439:112326.
    PubMed    
    Abstract available

  100. YAMAMOTO S, Fukata S, Kurano Y, Morishita Y, et al
    Fluorescence-guided local therapy for bladder and upper urinary tract cancer: a narrative review.
    Photodiagnosis Photodyn Ther. 2026;61:105617.
    PubMed    
    Abstract available

  101. MENON A, Koch R, Abramovich C
    Photo Quiz: Globose Yeast-Like Forms With Multiple Peripheral Buds in Urine and Cervical Cytology.
    Diagn Cytopathol. 2026;54:842-845.
    PubMed    
    Abstract available

  102. BUZOIANU MM, Andras I, Vesa S, Giurgiu L, et al
    A single-institutional analysis of laparoscopic 3D radical cystectomy with intracorporeal urinary diversion.
    BMC Urol. 2026;26:238.
    PubMed    
    Abstract available

  103. GUO B, Fu S, Li J, Cheng Q, et al
    An integrative epigenomic and single-cell framework identifies a prognostic DNA methylation risk score and ZNF638 silencing in urothelial carcinoma.
    J Transl Med. 2026;24:1264.
    PubMed    
    Abstract available

  104. ALVAREZ-OSSORIO JL, Alvarez-Maestro M, Cozar-Olmo JM, Espinosa-Bosch M, et al
    Recommendations for the prevention and treatment of adverse effects of intravesical BCG.
    Actas Urol Esp (Engl Ed). 2026;50:502005.
    PubMed    
    Abstract available

  105. LEON P, Long Depaquit T, Audenet F, Allory Y, et al
    Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC.
    Fr J Urol. 2026;36:103156.
    PubMed    
    Abstract available

  106. MATHEZ W, Briche V, Vincentelli A, Bruyere F, et al
    Clinical utility of routine urine culture before intravesical mitomycin C instillation: A retrospective instillation-based study.
    Fr J Urol. 2026;36:103154.
    PubMed    
    Abstract available

  107. MENEGHESSO D, Pasquinucci M, Bruniera M, Carletti F, et al
    Diagnosis by Resolution: Ultrasound Follow-Up of Neonatal Polypoid Cystitis Mimicking Botryoid Rhabdomyosarcoma.
    J Clin Ultrasound. 2026;54:2070-2074.
    PubMed    
    Abstract available

  108. CORBIN H, Khader S, Quiroga-Garza G, Pantanowitz L, et al
    When Small Cells Matter: Diagnosing Bladder Small Cell Carcinoma on Urine Cytology.
    Cytopathology. 2026;37:667-672.
    PubMed    
    Abstract available

  109. DONG X, Li Y, Yan Y, Xiong H, et al
    A cytoplasmic cis-acting circuit confines PI3K/AKT-driven lineage plasticity in bladder cancer.
    Cell Signal. 2026 Oct 16:112952. doi: 10.1016/j.cellsig.2026.112952.
    PubMed    
    Abstract available

  110. SHANG H, Yu S, Zhou Z, Wang D, et al
    pH-responsive biomimetic liposomes enhance targeted immunotherapy of bladder cancer.
    Sci China Life Sci. 2026 Oct 12. doi: 10.1007/s11427-026-3557.
    PubMed    
    Abstract available

  111. DINKEL H, Seifert KE, Bogemann M, Schrader AJ, et al
    Management of extravasations of enfortumab vedotin and pembrolizumab: a case report and mini review of the current literature.
    J Cancer Res Clin Oncol. 2026;152:197.
    PubMed    
    Abstract available

  112. OKUYAMA R, Horiuchi H, Nakamura M, Muroya M, et al
    Enhanced detection of bladder cancer using machine learning analysis of routine urinary sediment data.
    Clin Chem Lab Med. 2026 Oct 19. doi: 10.1515/cclm-2026-1514.
    PubMed    
    Abstract available

  113. WU YW, Yu EY, Chen YT, Li MH, et al
    Soy Consumption and the Risk of Developing Bladder Cancer: A Pooled Analysis of Cohort Studies from the International Pooled Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study.
    Nutrients. 2026;18:3110.
    PubMed    
    Abstract available

  114. ANDREU-INGLES M, Onoiu AI, Grifoll-Escoda M, Hernandez-Aguilera A, et al
    Urinary DNA Methylation Profiling Identifies a Biologically Distinct Subgroup of Low-Grade Urothelial Carcinoma with High-Grade-Associated Features.
    Int J Mol Sci. 2026;27:8934.
    PubMed    
    Abstract available

  115. MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
    FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2026;27:8698.
    PubMed    
    Abstract available

  116. WANG Z, Afshar N, Hodge AM, Jayasekara H, et al
    Consumption of Processed Meat and Unprocessed Red Meat and Risk of Bladder Cancer: A Pooled Analysis of 30 Cohort Studies.
    Cancers (Basel). 2026;18:3203.
    PubMed    
    Abstract available

  117. LI S, Li M, Zhang Y, Pu J, et al
    Metabolic Reprogramming in Bladder Cancer: Molecular Drivers, Immune Regulation and Therapeutic Opportunities.
    Cancers (Basel). 2026;18:3202.
    PubMed    
    Abstract available

  118. ZHONG X, Wang G, Zhang H, Shi Y, et al
    Bladder cancer organoids in precision medicine: bridging basic science, clinical therapeutics and drug development.
    Cancer Cell Int. 2026;26:340.
    PubMed    
    Abstract available

  119. DANESHMAND S, Boorjian SA, Meeks JJ, Lotan Y, et al
    Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies.
    Nat Rev Urol. 2026 Oct 15. doi: 10.1038/s41585-026-01193.
    PubMed    
    Abstract available

  120. SHELDON J, Holt S, Brewer E, Gore JL, et al
    Prospectively collected functional vs. self-reported frailty measures and postoperative outcomes after radical cystectomy in older adults with bladder cancer.
    Urol Oncol. 2026 Oct 16:S1078-1439(26)00736.
    PubMed    
    Abstract available

  121. SUBIELA JD, Gonzalez-Padilla DA, Scilipoti P, Slusarczyk A, et al
    Perioperative enfortumab vedotin-pembrolizumab, gemcitabine-cisplatin-durvalumab, and dose-dense MVAC in cisplatin-eligible muscle-invasive bladder cancer: A benefit-risk Bayesian network meta-analysis.
    Urol Oncol. 2026 Sep 22:S1078-1439(26)00738.
    PubMed    
    Abstract available

  122. SATO T, Hayata N, Miura T, Mishina M, et al
    Feasibility of Laparoscopic Partial Cystectomy for Bladder Paraganglioma: A Four-Case Series.
    Asian J Endosc Surg. 2026;19:e70394.
    PubMed    
    Abstract available

  123. YANG H, Zhang R, Zhang Z, Zhao K, et al
    [Conversion from Bricker to orthotopic neobladder: A case report].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2026;58:1095-1098.
    PubMed    
    Abstract available

  124. FUKUI K, Kobayashi M, Yoshida S, Arita Y, et al
    Diagnostic performance of post-chemoradiotherapy nacVI-RADS for identifying pathological complete response in muscle-invasive bladder cancer.
    Eur J Radiol. 2026;206:113292.
    PubMed    
    Abstract available

  125. LI Y, Li X, Jiang L, Sun L, et al
    Urinary cell TWIST1 methylation as a non-invasive dual biomarker: A Multicenter study for early detection and recurrence monitoring in bladder cancer.
    Cancer Genet. 2026;308-309:203-211.
    PubMed    
    Abstract available

  126. SHI Y, Zong X, Lian J, Wang Y, et al
    Nectin-4 and TROP-2 in bladder cancer: biomarkers for targeted therapy.
    Pathobiology. 2026 Oct 15:1. doi: 10.1159.
    PubMed    
    Abstract available

  127. SHYR CR, Shih CK, Wu CF, Ma WL, et al
    In Vitro and In Vivo Characterization of Porcine Urothelial Cells as an Intravesical Cellular Xenotransplantation Immunotherapeutic Agent for Bladder Cancer.
    Xenotransplantation. 2026;33:e70167.
    PubMed    
    Abstract available

  128. LIEDBERG F, Bobjer J, Hagberg O, Aljabery F, et al
    Lower proportion of bladder cancer diagnosed at unscheduled hospitalization after introduction of standardized care pathways in Sweden.
    Scand J Urol. 2026;61:241-246.
    PubMed    
    Abstract available

  129. HAN S, Li X, Ma L, Hu Z, et al
    Real-World Comparative Effectiveness of Lobaplatin Versus Epirubicin and Gemcitabine for Post-TURBT Intravesical Therapy in Non-Muscle-Invasive Bladder Cancer.
    Arch Esp Urol. 2026;79:1440-1449.
    PubMed    
    Abstract available

  130. TENG H, Chen J, Qian J, Chen L, et al
    Metabolic Syndrome and Bladder Cancer Risk: A Meta-Analysis of Cohort Studies.
    Arch Esp Urol. 2026;79:1419-1428.
    PubMed    
    Abstract available

  131. LI G, Cui J, Feng X, Li W, et al
    Single-Cell-Informed Characterization of A Candidate S100A9-Associated Epithelial Program and Prognostic Signature in Bladder Cancer.
    Arch Esp Urol. 2026;79:1381-1394.
    PubMed    
    Abstract available

  132. LIU X, Shi ZD, Wang GC, Wang JM, et al
    Serial H&E Pathology Reveals Progression-Associated Nuclear Size Drift as a Longitudinal Digital Readout of Bladder Cancer Evolution.
    Adv Sci (Weinh). 2026 Oct 14:e78299. doi: 10.1002/advs.78299.
    PubMed    
    Abstract available

  133. WIGNER-JEZIORSKA P, Grebowski R, Tokarz P, Plazuk D, et al
    Purine and citrate metabolism in urolithiasis and bladder cancer: An integrated genetic, gene-expression, and targeted metabolite analysis.
    Biochim Biophys Acta Mol Basis Dis. 2026 Oct 14:168500.
    PubMed    
    Abstract available

  134. PAN B, Zheng J, Luo Z, Hou S, et al
    Single-cell and spatial transcriptomics reveal a DLL4-associated tip-like endothelial niche linked to neoadjuvant chemotherapy non-response in muscle-invasive bladder cancer.
    Transl Oncol. 2026;74:103067.
    PubMed    
    Abstract available

  135. CHAI JL, Lan Z, Svystun O, Shaikh MJ, et al
    MR Imaging and Radiomics Features for Predicting Variant Histology of Bladder Cancer: A Single Centre Retrospective Analysis.
    J Med Imaging Radiat Oncol. 2026 Oct 14. doi: 10.1111/1754-9485.70193.
    PubMed    
    Abstract available

  136. ATIF K, Arif U, Gorish MA, Saleem SM, et al
    National trends and disparities in mortality involving bladder cancer and substance use disorders in the United States, 1999-2023.
    Front Oncol. 2026;16:1883338.
    PubMed    
    Abstract available

  137. CHEN C, Yang Y, Chen Z, Li X, et al
    Liquid biopsy in bladder cancer: towards precision oncology.
    J Transl Med. 2026;24:1294.
    PubMed    
    Abstract available

  138. GREIDANUS J, Bernabei C, Chupetvloska K, Agrotis G, et al
    Reproducibility and diagnostic performance of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: a multi-ROI comparison analysis from the phase-Ib NABUCCO trial.
    Insights Imaging. 2026;17:255.
    PubMed    
    Abstract available

  139. TAN YG, Dudinec J, Kamat AM, Lim BJH, et al
    Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study.
    Eur Urol Focus. 2026 Oct 13:S2405-4569(26)00221.
    PubMed    
    Abstract available

  140. NANJO GU, Fu Z, Smani S, Lokeshwar SD, et al
    Translational research models for variant subtype bladder cancers: A comprehensive review of the current landscape.
    Urol Oncol. 2026 Oct 13:S1078-1439(26)00735.
    PubMed    
    Abstract available

  141. KOHLER J, Rodler S
    Response to "Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival".
    Urol Oncol. 2026 Oct 13:S1078-1439(26)00746.
    PubMed    


  142. MCFARLANE L, Dugbartey GJ, McLeod P, Shamma T, et al
    Evaluation of hydrogen sulfide inhibition as an adjunct to gemcitabine and BCG therapy in non-muscle-invasive bladder cancer.
    Biomed Pharmacother. 2026;204:119983.
    PubMed    
    Abstract available

  143. HAN M, Park JH, Hong JY, Han K, et al
    Joint Associations of Abdominal Obesity, General Obesity, and Smoking with Bladder Cancer Risk Among Postmenopausal Women: A Nationwide Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed    
    Abstract available

  144. HU J, Wang Y, Du Y, Li X, et al
    SESN2 promotes ferroptosis in bladder cancer by negatively regulating the NRF2/FSP1 signaling axis.
    Transl Androl Urol. 2026;15:332.
    PubMed    
    Abstract available

  145. LI B, Ji G, Wang W, Guo L, et al
    An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation.
    Transl Androl Urol. 2026;15:341.
    PubMed    
    Abstract available

  146. SAHINI H, Anzengruber M, Lachelt U
    Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.
    Front Med (Lausanne). 2026;13:1979620.
    PubMed    
    Abstract available

  147. RAO XP, Zou XC, Liu X, Xu LY, et al
    Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.
    Front Immunol. 2026;17:1891151.
    PubMed    
    Abstract available

  148. SAFARINEJAD MR, Safarinejad S, Shafiei N, Safarinejad S, et al
    Retraction notice to "Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility" [Urologic Oncology: Seminars and Original Investigations 31 (2013) 1193-1203].
    Urol Oncol. 2026 Oct 12:S1078-1439(26)00701.
    PubMed    


  149. YAMAGUCHI M, Ide H, Kitaoka S, Nishimura C, et al
    [UROTHELIAL CARCINOMA WITH SARCOMATOID SUBTYPE OF THE BLADDER ACCOMPANIED BY TROUSSEAU'S SYNDROME: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2026;117:16-19.
    PubMed    
    Abstract available

  150. SAKURA Y, Yamashita R, Ito K, Shinsaka H, et al
    [CORRELATION BETWEEN RELATIVE DOSE INTENSITY AND TREATMENT OUTCOMES OF ENFORTUMAB VEDOTIN IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC UROTHELIAL CARCINOMA].
    Nihon Hinyokika Gakkai Zasshi. 2026;117:1-8.
    PubMed    
    Abstract available

  151. IKAI T, Shirane H, Yoshioka H, Akiyama K, et al
    [A CASE OF MALIGNANCY ARISING IN A NEOBLADDER MORE THAN 50 YEARS AFTER RECONSTRUCTION].
    Nihon Hinyokika Gakkai Zasshi. 2026;117:83-86.
    PubMed    
    Abstract available

  152. MOLLICA V, Rosellini M, Giannatempo P, Gupta S, et al
    Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trials.
    Crit Rev Oncol Hematol. 2026;228:105648.
    PubMed    
    Abstract available

  153. LI K, You G, Liu Z, Cheng X, et al
    Artemisitene targets GLIS3 to inhibit the NF-kappaB-TNF signaling pathway and suppress bladder cancer cell growth.
    Phytomedicine. 2026;162:158853.
    PubMed    
    Abstract available

  154. LOKE YL, Lim XY, Beishenaliev A, Goh SJ, et al
    Ultrasound-controlled therapeutics for bladder cancer: Mechanisms, recent advances, and future perspectives.
    Colloids Surf B Biointerfaces. 2026;270:116248.
    PubMed    
    Abstract available

  155. WANG D, Zhang Z, Wang Y, Wang Z, et al
    Interobserver agreement of non-parallel transmission technology zoomed-diffusion-weighted imaging (DWI) for ordinal biparametric Vesical Imaging-Reporting and Data System (VI-RADS)-based scoring in bladder cancer lesions >/=1 cm.
    Quant Imaging Med Surg. 2026;16:801.
    PubMed    
    Abstract available

  156. MOCHIZUKI T, Kawahara T, Hashizume A, Yamazaki M, et al
    Changes in the Age Distribution of Radical Prostatectomy and Radical Cystectomy During the Diffusion of Robot-Assisted Surgery in Japan.
    Cancer Med. 2026;15:e72370.
    PubMed    
    Abstract available

  157. SINGH A, Jain P
    CAF-derived GLG1 drives bladder cancer growth and apoptosis resistance.
    Apoptosis. 2026;31:247.
    PubMed    


  158. TURKOVIC AH, Stanecic Z, Butorac A, Kasuba V, et al
    Synergistic effects of combined exposure to hydroquinone and nitrofurantoin in T24 bladder cells: an in vitro toxicology study with implications for risk assessment.
    Arh Hig Rada Toksikol. 2026;77:169-181.
    PubMed    
    Abstract available

  159. SULHAN H, Akkoc Y, Akgollu E
    CYP24A1 rs1570669 and rs2762934 polymorphisms and bladder cancer susceptibility: a Turkish case-control study.
    Mol Biol Rep. 2026;53:1700.
    PubMed    
    Abstract available

  160. KLUGMAN Y, Cordero NM, Harrington G, Khan M, et al
    Impact of second-look TURBT on high grade recurrence and intravesical therapy in high-risk non-muscle-invasive bladder cancer: A 20-year experience.
    Urol Oncol. 2026 Oct 10:S1078-1439(26)00737.
    PubMed    
    Abstract available

  161. HUANG Z, Liu B, Li X, Jin C, et al
    Corrigendum to "RUNX2 enhances bladder cancer progression by promoting glutamine metabolism" [Neoplasia 60 (2025) 101120, doi: 10.1016/j.neo.2024.101120].
    Neoplasia. 2026;82:101373.
    PubMed    


  162. WANG Z, Jiang H, Hu C, Zhang H, et al
    MRI morphometric features and apparent diffusion coefficients predict muscle invasion in VI-RADS 3 bladder cancers.
    Clin Radiol. 2025;103:107206.
    PubMed    
    Abstract available

  163. LU J, Jiang Y, Jin Y, Zhang Y, et al
    Tumor-intrinsic execution of interferon-gamma-associated immunity in bladder cancer: checkpoints in signaling, recruitment, and recognition.
    Front Immunol. 2026;17:1979524.
    PubMed    
    Abstract available

  164. CHEN X, Liu S, Zhang X, Chen X, et al
    KRT14 activated by transcription factor E2F1 promotes bladder cancer progression.
    Oncol Lett. 2026;32:529.
    PubMed    
    Abstract available

  165. HAYNE D, Sengupta S, Zhang AY, Oliveira N, et al
    Australian Practical Guide on the Management of Muscle-Invasive Bladder Cancer.
    Asia Pac J Clin Oncol. 2026 Oct 9. doi: 10.1111/ajco.70207.
    PubMed    
    Abstract available

  166. GAO J, Murray BO, Wu Q, Fryer MT, et al
    Evaluation of a rapid-release mitomycin C-loaded porous microcapsule formulation (MitoCap) in a human urothelium-tumour model.
    Int J Pharm. 2026;704:127429.
    PubMed    
    Abstract available

  167. KAPAR C, Ozkan O, Eylemer Mocan E, Yaslikaya S, et al
    Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.
    Immunotherapy. 2026;18.
    PubMed    
    Abstract available

  168. WANG Y, Chen Z, Liu Z, Ma Z, et al
    Tumor cells recruit macrophage bodyguards to outlast chemotherapy.
    Cancer Cell. 2026;44:1930-1932.
    PubMed    
    Abstract available

  169. LI H, Bhardwaj S, Feng M, McNamara M, et al
    Lipid-Rich Urothelial Carcinoma: A Contemporary Clinicopathologic Study of 40 Patients With Transcriptional Tumor Profiling.
    Am J Surg Pathol. 2026;50:1269-1280.
    PubMed    
    Abstract available

  170. XIONG S, Li G, Wu Y, Liang Y, et al
    UCtracker: A Deep Learning-Based DNA Methylation Model for Noninvasive Diagnosis and Recurrence Surveillance of Urothelial Carcinoma in a Prospective Study.
    Adv Sci (Weinh). 2026;13:e76710.
    PubMed    
    Abstract available

  171. HONG YD, Enewold L, Zeruto CA, Mariotto AB, et al
    Receipt of Cancer Surgery: A Comparison of Cancer Registry Data and Medicare Claims.
    Med Care. 2026;64:787-792.
    PubMed    
    Abstract available

  172. HAN Y, She Y, Wei J, Zhang X, et al
    Clinical indicators combined with spectral CT in differentiating non-muscle-invasive bladder urothelial carcinoma from cystitis glandularis.
    Abdom Radiol (NY). 2026;51:5939-5949.
    PubMed    
    Abstract available

  173. ZHANG Z, Cao K, Li J, He Z, et al
    Federated Learning-Based Multi-Task Framework for Privacy-Preserving Diagnosis of Muscle Invasion in Bladder Cancer.
    J Imaging Inform Med. 2026 Oct 22. doi: 10.1007/s10278-026-02429.
    PubMed    
    Abstract available

  174. YAO J, Wang W, Li D, Xu C, et al
    The novel biguanide derivative 4C synergizes with talazoparib by inducing ferroptosis via the SREBP1/FASN/ SLC7A11/GPX4 axis in bladder cancer.
    Cell Death Discov. 2026;12:423.
    PubMed    
    Abstract available

  175. DU E, Wang W, Su Q, Huang W, et al
    NEK2-AURKA axis drives ubiquitin-dependent IFT88 degradation to suppress ciliogenesis and promote basal-type bladder cancer.
    Cell Death Dis. 2026;17:903.
    PubMed    
    Abstract available

  176. BEDKE J, Arkosy P, Nishiyama H, Mahammedi H, et al
    Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study.
    Ann Oncol. 2026 Oct 23:S0923-7534(26)06888-2. doi: 10.1016/j.annonc.2026.
    PubMed    
    Abstract available

  177. SONPAVDE G, van der Heijden MS, Gupta S, Galsky MD, et al
    Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial.
    Ann Oncol. 2026 Dec 31:S0923-7534(26)06877-8. doi: 10.1016/j.annonc.2026.
    PubMed    
    Abstract available

  178. FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
    Comparison of oral 5-aminolevulinic acid-induced hypotension between general and spinal anesthesia during photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2026 Oct 22:105685.
    PubMed    
    Abstract available

  179. MAN X, Dong C, Dong A, Song X, et al
    Intradiverticular Bladder Cancer Mimicking a Normal Urinary Bladder Diverticulum on FDG PET/CT.
    Clin Nucl Med. 2026 Oct 20. doi: 10.1097/RLU.0000000000006729.
    PubMed    
    Abstract available

  180. REN Y, Liu T, Hou X, Yao Y, et al
    Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma.
    J Med Chem. 2026;69:24388-24399.
    PubMed    
    Abstract available

  181. LIU Y, Xu Z, Xia J, Guo L, et al
    An interpretable contrast-enhanced CT-based cross-attention transformer model for predicting progression-free survival in muscle-invasive bladder cancer: a multicenter study.
    Abdom Radiol (NY). 2026 Oct 22. doi: 10.1007/s00261-026-05837.
    PubMed    
    Abstract available

  182. HIJAZI M, Hanna J, Sykes J, Golombos D, et al
    Novel Imaging Techniques Prior to Surgical Management of Invasive Bladder Cancer: A Systematic Review.
    Curr Urol Rep. 2026;27:58.
    PubMed    
    Abstract available

  183. MATHIS BJ, Nagumo Y, Kimura T, Ishikawa H, et al
    Patient-reported outcome sub-analysis of a phase 2 trial of bladder preservation therapy with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer.
    Int J Clin Oncol. 2026 Oct 22. doi: 10.1007/s10147-026-03226.
    PubMed    
    Abstract available

  184. XU DM, Li M, Lin H, Zhuang XY, et al
    Before the seeds arrive: pre-metastatic niche orchestration in bladder cancer.
    Cancer Metastasis Rev. 2026;45:79.
    PubMed    
    Abstract available

  185. CHEN S, Li X, Zhan P, Luo T, et al
    AFF3 regulates ferroptosis and malignant progression in bladder cancer cells via the NRF2/GPX4 signaling axis.
    Eur J Histochem. 2026;70.
    PubMed    
    Abstract available

  186. ZHANG C, Wei W, Cao S, Li Z, et al
    Exon-6 truncated p53 Suppresses Innate Immune Responses to Facilitate Immune Evasion in Bladder Cancer.
    Int J Biol Sci. 2026;22:8251-8270.
    PubMed    
    Abstract available

  187. ALBERS LF, van Gennep EJ, van der Heijden MS, Pos FJ, et al
    Clinical response outweighs baseline nodal stage in treatment selection and survival of clinically node-positive bladder cancer.
    World J Urol. 2026;44:759.
    PubMed    
    Abstract available

  188. ABOU CHAKRA M, Myers AA, Duquesne I, Mott SL, et al
    Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urol Pract. 2026 Oct 23:101097UPJ0000000000001109.
    PubMed    
    Abstract available

  189. JIANG M, Zhao D, Zhang L, Zhu D, et al
    Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer.
    Front Immunol. 2026;17:1958628.
    PubMed    
    Abstract available

  190. SUN Z, Xie R, Pan J, Zhu Y, et al
    Population-specific molecular features and clinical significance of urinary tumor DNA mutations in Chinese patients with newly diagnosed non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1914617.
    PubMed    
    Abstract available

  191. TSAI TF, Chang HC, Lin YY, Chen YC, et al
    Capsaicin enhances chemosensitivity and mitigates MMP11-driven aggressiveness in human bladder cancer.
    Cancer Cell Int. 2026;26:346.
    PubMed    
    Abstract available

  192. CHAKER K, Chaabouni A, Elleuch W, Khadhar A, et al
    Predicting acute kidney injury after radical cystectomy for muscle-invasive bladder cancer.
    BMC Urol. 2026;26:253.
    PubMed    
    Abstract available

  193. YAO Q, Niu H, Jiang H, Xu L, et al
    Guidewire-assisted en bloc resection of periorifice non-muscle-invasive bladder cancer: a retrospective case series.
    BMC Urol. 2026;26:252.
    PubMed    
    Abstract available

  194. VICKERS AJ, McSweeney DM, Choudhury A, Weaver J, et al
    DAG-informed analysis of muscle characteristics and overall survival in patients receiving radical treatment for bladder cancer.
    Radiother Oncol. 2026 Oct 21:111831. doi: 10.1016/j.radonc.2026.111831.
    PubMed    
    Abstract available

  195. WANG Y, Zhang S, Luo X, Wang Z, et al
    Integrative single-cell and computational pathology analyses reveal a C11orf24-associated stem-like epithelial population linked to tumor microenvironment remodeling and immune evasion in bladder cancer.
    Transl Oncol. 2026;74:103082.
    PubMed    
    Abstract available

  196. HONG G, Jiang F, Xie Y, Huang X, et al
    Multitask Deep Learning Model for Predicting Lymph Node Metastasis and Disease-Free Survival From Cytology Images in Bladder Cancer: A Multicenter Study With Pan-Cytology Validation.
    Adv Sci (Weinh). 2026 Oct 21:e76577. doi: 10.1002/advs.76577.
    PubMed    
    Abstract available

  197. HRECHKO BO, Voylenko O, Vitruk I, Stakhovsky O, et al
    Cytoreductive cystectomy combined with chemotherapy versus chemotherapy alone in the treatment of metastatic bladder cancer: A retrospective comparative study.
    Cent European J Urol. 2026;79:233-242.
    PubMed    
    Abstract available

  198. PAKOVSKI K, Markova M, Janchulev J, Ambardjieva M, et al
    FGFR3 mRNA expression in urothelial bladder cancer: Associations with tumor phenotype without prognostic impact.
    Cent European J Urol. 2026;79:295-302.
    PubMed    
    Abstract available

  199. YANG M, Guo Y, Shen YZ, Sun YL, et al
    Reprogramming innate immune memory in bladder cancer: the proposed bone marrow-bladder axis and next-generation BCG-based immunotherapies.
    Front Immunol. 2026;17:1945559.
    PubMed    
    Abstract available

  200. PATEL SR, Rauf M, Geng Y, Hinojosa-Gonzalez D, et al
    Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Oncol. 2026 Oct 20:S2588-9311(26)00275.
    PubMed    
    Abstract available

  201. LI Y, Zuo L, Dong X, Sun R, et al
    NU-1025 modulates immunogenic cell death in bladder cancer: A multi-omics insight.
    SLAS Technol. 2026;43:100476.
    PubMed    
    Abstract available

  202. SHAMSEDDINE A, Abbas N, Eichholz J, Chatila WK, et al
    Mutational Signatures and Hypermutation Phenotypes Define Bladder Cancers Arising in Waterpipe and Cigarette Smokers.
    Mol Cancer Res. 2026 Oct 20. doi: 10.1158/1541-7786.MCR-26-0157.
    PubMed    
    Abstract available

  203. SU ZT, Garman TS, Rivera Lopez CA, Talwar R, et al
    Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer.
    JAMA Netw Open. 2026;9:e2640370.
    PubMed    
    Abstract available

  204. HE X, Zhang H, Zhang Y, Wu J, et al
    MG53 suppresses the progression of bladder cancer through E3 ubiquitin ligase-mediated degradation of AMPKalpha.
    Med Oncol. 2026;43:337.
    PubMed    
    Abstract available

  205. ISMAIL Y, Kamal A, Aboulkassem H, Ashour MG, et al
    Bladder preservation is still feasible in the rare aggressive small cell carcinoma subtype.
    Med Oncol. 2026;43:339.
    PubMed    
    Abstract available

  206. YIN Z, Ho JWK
    The Current Status and Evaluation of Artificial Intelligence in Bladder Cancer: Clinical Applications and Research.
    Comput Struct Biotechnol J. 2026;35:0197.
    PubMed    
    Abstract available

  207. LI S, Chen H, Feng B
    Bioengineering strategies to enhance BCG immunotherapy against bladder cancer.
    Front Immunol. 2026;17:1888889.
    PubMed    
    Abstract available

  208. HAN X, Xie L, Li Z, Hou Y, et al
    Echinocystic acid inhibits the growth of human bladder cancer cells by suppressing AKT1/GSKbeta/beta-Catenin signaling and synergizes with gemcitabine.
    Genes Dis. 2026;14:102148.
    PubMed    
    Abstract available

  209. ALKAN GV, Dogan K, Turk Alkan M, Onder E, et al
    Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral grade heterogeneity.
    Pathol Oncol Res. 2026;32:1612553.
    PubMed    
    Abstract available

  210. JIN Y, Jin Y, Cui Y
    Bladder cancer in Africa, 2010-2023: burden, geographic heterogeneity, demographic drivers, pandemic-era temporal changes, and projections to 2030.
    Infect Agent Cancer. 2026;21:69.
    PubMed    
    Abstract available

  211. CHEN JY, Ke ZB, Lin B, Liu MX, et al
    The NEK8/ALYREF axis promotes cisplatin resistance in bladder cancer by stabilizing CDK18 mRNA to facilitate DNA damage repair.
    Cell Death Differ. 2026 Oct 19. doi: 10.1038/s41418-026-01883.
    PubMed    
    Abstract available

  212. SAYGILI Y, Kose HC, Kose SG, Akkaya OT, et al
    A prospective randomized controlled trial comparing subpectineal and interfascial obturator nerve block techniques in preventing adductor muscle spasm during transurethral resection of bladder tumors.
    BMC Anesthesiol. 2026;26:622.
    PubMed    
    Abstract available

  213. XU H, Li Z, Yang L, Zheng J, et al
    Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation.
    IMetaOmics. 2026;3:e70081.
    PubMed    
    Abstract available

  214. LIANG T, Xu W, Fang H, Fu L, et al
    Integrin alpha5beta1-mediated multicellular crosstalk in the tumor microenvironment drives bladder cancer progression and reveals targetable vulnerabilities.
    IMetaOmics. 2026;3:e70102.
    PubMed    
    Abstract available

  215. GABRIEL PE, Marcq G, Zhu A, Sfakianos JP, et al
    Circulating Plasma and Urine Tumor DNA in Non-muscle-invasive Bladder Cancer: A Promising Biomarker to Guide Therapeutic Intensification.
    Eur Urol Open Sci. 2026;92:71-74.
    PubMed    
    Abstract available

  216. WU L, Qiao X, Wang W, Qiu J, et al
    Metabolic Competition-Driven Antitumor Immunity of glpX-Deficient Engineered Salmonella via Glucose Deprivation and STING Activation in Bladder Cancer.
    Cancer Commun (Lond). 2026;46:0060.
    PubMed    
    Abstract available

  217. IBRAHIM Y, Ribeiro L, Heelan M, Spazzapam M, et al
    NEITHER study: NICE versus EAU inconsistent triage, expenses and reliability in non-high-risk non-muscle invasive bladder cancer surveillance.
    BJUI Compass. 2026;7:e70283.
    PubMed    
    Abstract available

  218. YUAN F, Li X, Zhang J, Gao JY, et al
    Risk factors for recurrence after initial transurethral resection of bladder tumor in patients with non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1861461.
    PubMed    
    Abstract available

  219. MA Y, Zhang Z, Tang L, Li Q, et al
    Development and validation of a ferroptosis and metabolic reprogramming gene signature for risk stratification in bladder urothelial carcinoma: A retrospective multicohort study.
    Medicine (Baltimore). 2026;105:e51078.
    PubMed    
    Abstract available

  220. BULKLEY JE, O'Keeffe-Rosetti M, Leo MC, Gilbert SM, et al
    Recovery after cystectomy and urinary diversion: patient experiences and challenges.
    Support Care Cancer. 2026;34:1113.
    PubMed    
    Abstract available

  221. LIU S, Lu J, Lyu Z, Lu Z, et al
    Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling.
    Immunotherapy. 2026;18:1111-1125.
    PubMed    
    Abstract available

  222. ZEINALKHANI F, Kamali Hakim P, Sharifi A, Azizzadeh A, et al
    Age as a pre-operative predictor of uterine, bladder, and intestinal invasion in cervical cancer.
    Acta Radiol. 2026 Sep 16:2841851261486043. doi: 10.1177/02841851261486043.
    PubMed    
    Abstract available

  223. ZHAO T, Nawrocki C, Xiong L, Nieman LT, et al
    Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid Urothelial Carcinoma Reveals Distinct Molecular Landscapes.
    Lab Invest. 2026;106:106160.
    PubMed    
    Abstract available

  224. MUELLER NM, Christensen CA, Mullane EM, Iacob CE, et al
    METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER TO THE RETINA: A CLINICOPATHOLOGIC CORRELATION AND REVIEW OF THE LITERATURE.
    Retina. 2026;46:2076-2080.
    PubMed    
    Abstract available

  225. ITO A, Arai Y, Kakehi Y, Yokoyama M, et al
    Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2026;27:973-982.
    PubMed    
    Abstract available

  226. DITONNO F, Veccia A, Musso G, Derweesh IH, et al
    Metachronous Contralateral Recurrence in Upper Tract Urothelial Carcinoma: A Multi-Institutional Competing-Risks Analysis From the ROBUUST 3.0 Registry.
    Urol Pract. 2026;13:623-632.
    PubMed    
    Abstract available

  227. VAZQUEZ-ESTEVEZ S, Lazaro-Quintela M, Perez-Fentes D, Esteban-Gonzalez E, et al
    Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.
    Clin Transl Oncol. 2026;28:5031-5054.
    PubMed    
    Abstract available

  228. YADAV S, Madhavan K, Yadav A, Khurana U, et al
    A prospective cohort study to assess the diagnostic accuracy of VI-RADS score in a tertiary center in central India.
    Urologia. 2026;93:682-687.
    PubMed    
    Abstract available

  229. CILLI M, Onol SY
    Comparison of complications in our extraperitoneal radical cystoprostatectomy with orthotopic urinary diversion cases and the intraperitoneal approach reported in the literature.
    Urologia. 2026;93:674-681.
    PubMed    
    Abstract available

  230. KANEKO GO, Igarashi D, Morita M, Tsubota S, et al
    Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma.
    Anticancer Res. 2026;46:5715-5727.
    PubMed    
    Abstract available

  231. FUKUSHIMA H, Yoshida S, Yajima S, Hirakawa A, et al
    Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.
    Anticancer Res. 2026;46:5729-5735.
    PubMed    
    Abstract available

  232. WAKAMIYA T, Iwagami S, Enyo N, Shibano S, et al
    Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study.
    Anticancer Res. 2026;46:5639-5650.
    PubMed    
    Abstract available

  233. ESCRIG JLD, Black P, Inokuchi J, Kulkarni G, et al
    Real-world radical cystectomy use in high-risk non-muscle-invasive bladder cancer: a global survey.
    BJU Int. 2026 Oct 2. doi: 10.1111/bju.70480.
    PubMed    
    Abstract available

  234. TOUMAZOS K, Bell S, Spencer K, Nakagawa D, et al
    Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints.
    BJU Int. 2026 Sep 28. doi: 10.1111/bju.70461.
    PubMed    
    Abstract available

  235. WANG J, Zhao Y, Ye Y, Qi X, et al
    Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence.
    BJU Int. 2026 Oct 11. doi: 10.1111/bju.70488.
    PubMed    
    Abstract available

  236. MELLE-HANNAH M, Kjolhede H, Backdahl H, Johansson ME, et al
    First-in-human outpatient management of recurrent NMIBC with the Multi4 instrument.
    BJU Int. 2026;138:867-876.
    PubMed    
    Abstract available

  237. LEHNER F, Dugas S, Birkhauser V, Gross O, et al
    Bladder washing cytology in the initial evaluation of patients with neuro-urological disorders: to do or not to do?
    BJU Int. 2026;138:860-866.
    PubMed    
    Abstract available

  238. MUNK L, Hyldgaard JM, Kumasegaram V, Milling RV, et al
    Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial.
    BJU Int. 2026;138:831-840.
    PubMed    
    Abstract available

  239. DEPALMA M, Rossi F, Ferro M, Bukavina L, et al
    Enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer: efficacy proven, duration unclear.
    BJU Int. 2026 Oct 21. doi: 10.1111/bju.70507.
    PubMed    


  240. GUERRERO QUILES C, Abumanhal-Masarweh H, G Abalos J, Lodhi T, et al
    A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer.
    Br J Cancer. 2026 Sep 26. doi: 10.1038/s41416-026-03603.
    PubMed    
    Abstract available

  241. MAENOSONO R, Nishimura K, Tsujino T, Yoshikawa Y, et al
    Multiplex Immunofluorescence-defined CXCL13-associated TLS-like Niches Predict Outcome in Bladder Cancer.
    Clin Cancer Res. 2026 Sep 29. doi: 10.1158/1078-0432.CCR-26-1878.
    PubMed    
    Abstract available

  242. DAVIS LE, Basourakos SP, Calaway AC
    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Oct 1:S0302-2838(26)01999-8. doi: 10.1016/j.eururo.2026.
    PubMed    


  243. DING D, Wei W, Chen H, Tan W, et al
    Reply to Pierre-Etienne Gabriel and Evanguelos Xylinas's Letter to the Editor re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur
    Eur Urol. 2026 Oct 1:S0302-2838(26)02000-2. doi: 10.1016/j.eururo.2026.
    PubMed    


  244. SLUSARCZYK A, Uleri A, Radziszewski P, Pradere B, et al
    Re: Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.e
    Eur Urol. 2026 Oct 1:S0302-2838(26)02070-1. doi: 10.1016/j.eururo.2026.
    PubMed    


  245. SCILIPOTI P, Montorsi F
    Re: Matthew D. Galsky and Andrea Necchi. Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.07.014.
    Eur Urol. 2026 Sep 26:S0302-2838(26)02418-8. doi: 10.1016/j.eururo.2026.
    PubMed    


  246. MOLLICA V, Rosellini M, Santoni M, Massari F, et al
    Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer.
    Eur Urol. 2026 Oct 7:S0302-2838(26)02409-7. doi: 10.1016/j.eururo.2026.
    PubMed    


  247. AYDOGDU C, Bukavina L, Cheng L, Al-Ahmadie HA, et al
    Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.
    Eur Urol. 2026;90:377-388.
    PubMed    
    Abstract available

  248. HAYNE D, Spalding L, Hawks C, McCombie S, et al
    Validation of a Computational Histology Artificial Intelligence-based Biomarker for BCG Treatment in Non-muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial.
    Eur Urol. 2026 Oct 21:S0302-2838(26)02433-4. doi: 10.1016/j.eururo.2026.
    PubMed    


  249. IKEDA R, Yoshida S, Chen W, Fujiwara M, et al
    Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis.
    Int J Urol. 2026;33:e70667.
    PubMed    
    Abstract available

  250. HASHIMOTO M, Tomiyama E, Inoki L, Miki K, et al
    Urinary Extracellular Vesicle-Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer.
    Int J Urol. 2026;33:e70656.
    PubMed    
    Abstract available

  251. ZENG D, Li J
    From Biofluid Detectability to Bladder-Cancer-Specific Validation: Interpreting CTSV as a Noninvasive Biomarker.
    Int J Urol. 2026;33:e70650.
    PubMed    


  252. TOMIOKA S, Inoue S, Kawase R, Nagasaka Y, et al
    Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.
    Int J Urol. 2026;33:e70679.
    PubMed    
    Abstract available

  253. KATAYAMA S, Kawada T, Mori K, Iwatani K, et al
    Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma.
    Int J Urol. 2026;33:e70664.
    PubMed    
    Abstract available

  254. LEE JH, Lee CU, Song W, Sung HH, et al
    Role of neoadjuvant chemotherapy in micropapillary urothelial carcinoma: a multi-institutional analysis from the Korean Bladder Cancer Research Group.
    Int Urol Nephrol. 2026 Oct 1. doi: 10.1007/s11255-026-05412.
    PubMed    
    Abstract available

  255. HAYASHI Y, Yamashita R, Sakura Y, Sugino T, et al
    Concurrent extension of bladder cancer to the intramural ureter and prostatic urethra increases the risk of urethral cancer in patients undergoing radical cystectomy.
    Int Urol Nephrol. 2026 Sep 26. doi: 10.1007/s11255-026-05408.
    PubMed    
    Abstract available

  256. GAO F, Chen X, Gao W, Cheng Q, et al
    Two-step enucleation combined with needle electrode: a modified TURBT technique to enhance detrusor muscle detection.
    Int Urol Nephrol. 2026;58:4739-4750.
    PubMed    
    Abstract available

  257. GAFFNEY CD, Alam SM, Wald G, Sjoberg D, et al
    A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guerin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2026 Oct 1:101097JU0000000000005324. doi: 10.1097/JU.0000000000005324.
    PubMed    
    Abstract available

  258. DECASTRO GJ, Joffe BI, Stein MN, Abate-Shen C, et al
    A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guerin-Unresponsive Urothelial Carcinoma of the Bladder.
    J Urol. 2026;216:676-684.
    PubMed    
    Abstract available

  259. CHANG SS, Chamie K, Seabury CA, Gonzalgo ML, et al
    Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ +/- Papillary Disease.
    J Urol. 2026;216:663-675.
    PubMed    
    Abstract available

  260. HE W, Chen Q, Wang Z, Wang M, et al
    Single?cell multi?omics analysis reveals TGF-beta1-RUNX2-mediated matCAF differentiation and its role in remodeling the lymph node metastatic microenvironment in bladder cancer.
    Oncogene. 2026 Oct 23. doi: 10.1038/s41388-026-04022.
    PubMed    
    Abstract available

  261. JOJIMA K, Minato A, Tsubonuma Y, Mizushima Y, et al
    Patient-reported outcome-informed individualized dose and schedule modification of enfortumab vedotin plus pembrolizumab in a nonagenarian patient with metastatic bladder cancer: a case report.
    Urol Int. 2026 Oct 21:1. doi: 10.1159.
    PubMed    
    Abstract available

  262. TALLMAN JE, Hyman MJ, Agarwal PK, Faris SF, et al
    Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.
    Urology. 2026 Oct 9:S0090-4295(26)00665-5. doi: 10.1016/j.urology.2026.
    PubMed    
    Abstract available

  263. ERGAS IJ, Zimbalist A, Haque R, Lee VS, et al
    Diet quality and prognosis in patients with non-muscle invasive bladder cancer: the Be-Well Study.
    Urology. 2026 Oct 15:S0090-4295(26)00668-0. doi: 10.1016/j.urology.2026.
    PubMed    
    Abstract available

  264. SAKAI R, Shimada H, Hata S, Yokoyama A, et al
    Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells.
    BMC Cancer. 2026;26:1283.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum


;